Abstract
The authors report the long-term course of two siblings with L-dopa responsive dystonia (DRD) associated with a compound heterozygous mutation in the tyrosine hydroxylase (TH) gene. Both siblings manifested with lower-limb onset generalized DRD and had a sustained response to low-dose L-dopa therapy for over 35 years. Although the l-dopa therapy was delayed up to 20 years after disease onset, there were no cognitive or neurologic sequelae of the long-term catecholamine deficit.
MeSH terms
-
Adult
-
Age of Onset
-
Brain / enzymology
-
Brain / pathology
-
Brain / physiopathology
-
Brain Chemistry / genetics*
-
Catecholamines / biosynthesis
-
Catecholamines / deficiency*
-
DNA Mutational Analysis
-
Disease Progression
-
Dopamine Agents / adverse effects
-
Dopamine Agents / therapeutic use
-
Dystonia / drug therapy
-
Dystonia / enzymology*
-
Dystonia / genetics
-
Heterozygote
-
Humans
-
Levodopa / adverse effects
-
Levodopa / therapeutic use*
-
Longitudinal Studies
-
Magnetic Resonance Imaging
-
Male
-
Middle Aged
-
Panic Disorder / chemically induced
-
Point Mutation / genetics*
-
Siblings
-
Time
-
Tyrosine 3-Monooxygenase / deficiency*
-
Tyrosine 3-Monooxygenase / genetics
Substances
-
Catecholamines
-
Dopamine Agents
-
Levodopa
-
Tyrosine 3-Monooxygenase